IDXX
IDEXX Laboratories, Inc.NASDAQHealthcare$569.55+0.87%OpenMarket Cap: $45.35B
As of 2026-04-06
Valuation
P/E (TTM)
42.80
PEG
2.21
P/B
28.42
P/S
10.54
EV/EBITDA
30.64
DCF Value
$165.06
FCF Yield
2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
61.8%
Operating Margin
31.6%
Net Margin
24.6%
ROE
69.8%
ROA
37.5%
ROIC
40.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.09B | 60.3% | $315.6M | $248.2M | $3.08 | — |
| FY 2025 | $4.30B | 61.8% | $1.36B | $1.06B | $13.08 | — |
| Q3 2025 | $1.11B | 61.8% | $354.8M | $274.6M | $3.40 | — |
| Q2 2025 | $1.11B | 62.6% | $373.0M | $294.0M | $3.63 | — |
| Q1 2025 | $998.4M | 62.4% | $316.5M | $242.7M | $2.96 | — |
| Q4 2024 | $954.3M | 59.8% | $261.7M | $216.1M | $2.62 | — |
| FY 2024 | $3.90B | 61.0% | $1.13B | $887.9M | $10.67 | — |
| Q3 2024 | $975.5M | 61.1% | $303.9M | $232.8M | $2.80 | — |
| Q2 2024 | $1.00B | 61.9% | $263.8M | $203.3M | $2.44 | — |
| Q1 2024 | $964.1M | 61.5% | $299.0M | $235.6M | $2.81 | — |
| Q4 2023 | $901.6M | 58.4% | $245.3M | $194.5M | $2.32 | — |
| FY 2023 | $3.66B | 59.8% | $1.10B | $845.0M | $10.06 | — |